Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis

Yamashita, Shugo; Katsumi, Hidemasa; Hibino, Nozomi; Isobe, Yugo; Yagi, Yumiko; Tanaka, Yuka; Yamada, Saki; Naito, Chihiro; Yamamoto, Akira

doi:10.1016/j.biomaterials.2017.10.053

Cited by 57 publications

(35 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SEM image of nanoparticles showed that particles were spherical in shape and do not show considerable variation in shape as evident from figure 5. The results are in accordance with previous report (Moosavian et al, 2016;Pillai et al, 2015;Yamashita et al, 2018).…”

Section: Resultssupporting

confidence: 93%

Assessment of release kinetics of Docetaxel loaded PLGA nanoparticles

Mody¹,

Sharma²,

Vyas³

2019

Asian J Pharm Pharmacol

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 93%

Assessment of release kinetics of Docetaxel loaded PLGA nanoparticles

Mody¹,

Sharma²,

Vyas³

2019

Asian J Pharm Pharmacol

View full text Add to dashboard Cite

“…At present, research about paclitaxel dosage forms include liposomes, 4,5 polymeric micelles or nanoparticles, 6,7 nanocrystallines, [8][9][10][11] mesoporous materials inclusion, [12][13][14] and so on. The use of paclitaxel nanoparticles as a potential dosage form has attracted the attention of researchers.…”

Section: Introductionmentioning

confidence: 99%

Pure paclitaxel nanoparticles: preparation, characterization, and antitumor effect for human liver cancer SMMC-7721 cells

Gao

Liu

et al. 2018

IJN

View full text Add to dashboard Cite

IntroductionPure paclitaxel nanoparticles (PPN), consisting entirely of drug molecules, were prepared by the electrostatic spraying method as promising candidates for antitumor application. Compared with the traditional preparation method, the advantage of the electrostatic spraying method included high production rates, relatively small particle sizes, and ease of preparation.Materials and methodsPaclitaxel was used to prepared PPN by electrostatic spray. The electrostatic spray device included a constant speed pump with a syringe, a high-voltage power supply, and a metal foil receiver was used to prepare and evaluate PPN. The syringe drew off a certain amount of paclitaxel chloroform solution (150 μg/mL) and was placed on the constant speed injection pump. The dissolution behavior of PPN was evaluated by dissolution test and the presence of paclitaxel in PPN was detected by X-Ray powder diffraction and differential scanning calorimetry. Effect of PPN on SMMC-7721 cells were studied by cell uptake, cell apoptosis and antitumor study.ResultsThe results of X-ray powder diffraction and differential scanning calorimetry characterization showed that the PPN were in an amorphous state. A dissolution study indicated that PPN have a significantly enhanced dissolution rate of paclitaxel. Moreover, SMMC-7721 tumor cells treated with PPN exhibited a distinctly high uptake rate that promoted cell apoptosis. An in vivo antitumor study demonstrated that PPN had significant antitumor efficacy.ConclusionAll conclusions verified that electrostatic spraying is a potential technology for developing PPN, and PPN can be regarded as a promising treatment for cancer.

show abstract

“…The in vivo analysis in mice showed that probes with six or more acidic repeat sequences were accumulated into the bone. In addition, acidic oligopeptide conjugated drug delivery carriers were developed for bone targeted therapy 30,31 . The use of acidic oligopeptides for bone imaging is an attractive option, because they exhibit no apparent side-effects and have a shorter half-life in vivo compared to bisphosphonates.…”

Section: Discussionmentioning

confidence: 99%

Selection and identification of a novel bone-targeting peptide for biomedical imaging of bone

Bang

Park

Yoo

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The global burden of bone-related diseases is increasing in the aging society; thus, improved bone targeted imaging for their early identification and treatment are needed. In this study, we screened novel peptide ligands for hydroxyapatite, a major inorganic component of teeth and bones, and identified a peptide enabling in vivo bone targeting and real-time fluorescence bone detection. To isolate peptides highly specific for hydroxyapatite, we used negative and positive selection from a randomized 8-mer peptide phage library and identified hydroxyapatite-specific peptides (HA-pep2, HA-pep3, and HA-pep7). Among these three peptides, HA-pep3 showed the highest binding capacity and superior dissociation constant towards hydroxyapatite surfaces over time (~ 88.3% retained on hydroxyapatite after two weeks). Furthermore, HA-pep3 was highly specific for hydroxyapatite compared to other calcium salt-based materials. Using this superior specificity, HA-pep3 showed higher accumulation in skull, spine, and joints in comparison with scrambled control peptide during real-time whole-body imaging. Ex vivo analysis of the major organs and bone from mice demonstrated that the fluorescence intensity in bone was about 3.32 folds higher in the case of HA-pep3 than the one exhibited by the scrambled control peptide. Our study identified a novel approach for targeting ligands for bone specific imaging and can be useful for drug delivery applications.

show abstract

Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis

Cited by 57 publications

References 44 publications

Assessment of release kinetics of Docetaxel loaded PLGA nanoparticles

Assessment of release kinetics of Docetaxel loaded PLGA nanoparticles

Pure paclitaxel nanoparticles: preparation, characterization, and antitumor effect for human liver cancer SMMC-7721 cells

Selection and identification of a novel bone-targeting peptide for biomedical imaging of bone

Contact Info

Product

Resources

About